Seer Appoints Rachel Haurwitz, Ph.D., to its Board of Directors
Seer, Inc. (Nasdaq: SEER) has appointed Rachel Haurwitz, Ph.D., CEO of Caribou Biosciences, to its Board of Directors effective November 8, 2021. Haurwitz's extensive experience in genome editing is expected to bolster Seer's mission in proteomics. David Singer will step down from the board, marking a significant leadership transition. The addition of Haurwitz, a recognized figure in the biotechnology field, reflects Seer’s commitment to advancing its innovative Proteograph technology aimed at enhancing biological insights.
- Appointment of Rachel Haurwitz is expected to enhance strategic leadership in proteomics.
- Haurwitz's expertise in gene editing could drive innovation and growth for Seer.
- Positive continuity in leadership with a focus on advancing the Proteograph technology.
- David Singer's departure may raise concerns about board continuity and experience.
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Rachel Haurwitz, Ph.D. to serve on its Board of Directors, effective November 8, 2021. Dr. Haurwitz is currently CEO of Caribou Biosciences, Inc. a clinical-stage biopharmaceutical company developing genome-edited off-the-shelf immune cell therapies for the treatment of cancer. Concurrent with this appointment, David Singer will step down from the Board of Directors.
“We’re delighted to welcome Rachel to our Board of Directors. Rachel is a highly accomplished and distinguished scientist and CEO in the high-growth, emerging area of gene editing,” said Omid Farokhzad, M.D., Chair, Chief Executive Officer and Founder of Seer. “Rachel’s passion for our work at Seer, coupled with her expertise, will contribute to our growth and the delivery of our promise of opening up a new gateway to the proteome. I would like to thank David for the invaluable role he has played to help position Seer as a leader in proteomics, as well as his guidance during our transition from a private to public company.”
“I am excited to join the Seer Board and eager to contribute to the company’s inspiring mission,” said Dr. Haurwitz. “As Seer’s technology redefines what’s possible in proteomics, I look forward to partnering with their talented leadership team to deliver on this remarkable promise of opening up new insights in biology to transform human health.”
Rachel Haurwitz is a co-founder of Caribou Biosciences, Inc. and has been its President and Chief Executive Officer and a director since the company’s inception in 2011. Rachel is an inventor on patents and patent applications covering multiple CRISPR-based technologies and has co-authored several scientific papers in high-impact journals characterizing CRISPR-Cas systems. In 2018, the Association for Women in Science recognized Rachel with the annual Next Generation Award. She serves on the board of directors of the Biotechnology Organization (BIO). Rachel earned an A.B. in Biological Sciences from Harvard College and a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.
About Seer Inc.
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer is commercializing its Proteograph™ Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Investor Contact
Carrie Mendivil
investor@seer.bio
Media Contact
Karen Possemato
pr@seer.bio
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b652d7c4-3120-4d8d-ae4a-3f1b5cb7fe2d
FAQ
Who is the new board member appointed at Seer, Inc. in November 2021?
What is the date of Rachel Haurwitz's appointment to Seer, Inc.'s Board?
What role did David Singer play at Seer, Inc. before stepping down?
What is Rachel Haurwitz's background in relation to biotechnology?
How might Rachel Haurwitz's appointment impact Seer, Inc.'s future?
